Biohaven Ltd. (BHVN) is refocusing on three late-stage clinical programs and implementing a 60% R&D cost reduction after significant financial and share price losses. BHVN's pipeline includes Opakalim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results